CAS · 192725-17-0
Product Overview
Lopinavir丨CAS 192725-17-0 is an antiretroviral medication belonging to the class of protease inhibitors (PIs). It is widely used in the treatment of HIV-1 infections and is most commonly administered in combination with Ritonavir (as the combination drug Kaletra), which boosts Lopinavir's bioavailability by inhibiting its metabolism via CYP3A enzymes.
Product Specifications
| Appearance | White powder |
|---|---|
| Assay (on the anhydrous and solvent-free basis) | 98.0~102.0% |
| Identification | HPLC, IR Conform |
| Water | 4.4% max |
| Residue on Ignition | 0.2% max |
| Heavy Metals | 20 ppm max |
| Any Other Individual Impurity | 0.1% max |
| Total Impurities | 0.7% max |
| Ethyl Acetate | 5000 ppm max |
| Ethanol | 5000 ppm max |
| Dimethylformamide | 880 ppm max |
| 2-Propanol | 5000 ppm max |
| N-Heptane | 5000 ppm max |
| Methylene Dichloride | 600 ppm max |
Applications
1. HIV/AIDS Therapy
Lopinavir is used as part of highly active antiretroviral therapy (HAART) to:
Inhibit the HIV protease enzyme.
Prevent viral replication.
Lower viral load and increase CD4+ T-cell counts.
2. Pediatric Use
Formulated as a liquid or oral solution, making it suitable for children and infants with HIV.
3. Research in Emerging Viruses
Investigated for potential antiviral activity against coronaviruses (e.g., SARS-CoV, MERS-CoV, and SARS-CoV-2), though efficacy remains unconfirmed in clinical settings.
Benefits
✅ Potent Protease Inhibition
Lopinavir binds to the active site of HIV protease, blocking the cleavage of the Gag-Pol polyprotein, leading to the production of immature, non-infectious viral particles.
✅ Boosted Efficacy with Ritonavir
Co-administered Ritonavir inhibits cytochrome P450 3A4, significantly increasing the plasma levels of Lopinavir, allowing for:
Reduced dosage frequency.
Enhanced therapeutic effect.
✅ Well-Studied and Widely Used
Extensively used in adult and pediatric populations worldwide.
Included in WHO Model List of Essential Medicines.
✅ Combination Therapy
Compatible with nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), allowing for flexible combination regimens.
Conclusion
Lopinavir丨CAS 192725-17-0 is a key antiretroviral protease inhibitor used primarily in combination with Ritonavir for the treatment of HIV-1 infection. Known for its potent antiviral activity and established clinical profile, Lopinavir plays an important role in both adult and pediatric HIV care, with additional exploratory research into its effects on other viral pathogens.
Previous
Next